315 related articles for article (PubMed ID: 29492843)
1. The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.
Diamantopoulos A; Wright E; Vlahopoulou K; Cornic L; Schoof N; Maher TM
Pharmacoeconomics; 2018 Jul; 36(7):779-807. PubMed ID: 29492843
[TBL] [Abstract][Full Text] [Related]
2. Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review.
Vaidya S; Hibbert CL; Kinter E; Boes S
Lung; 2017 Feb; 195(1):1-8. PubMed ID: 27866277
[TBL] [Abstract][Full Text] [Related]
3. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.
Collard HR; Chen SY; Yeh WS; Li Q; Lee YC; Wang A; Raghu G
Ann Am Thorac Soc; 2015 Jul; 12(7):981-7. PubMed ID: 25923447
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi Panel.
Morell F; Esser D; Lim J; Stowasser S; Villacampa A; Nieves D; Brosa M
BMC Pulm Med; 2016 Jan; 16():7. PubMed ID: 26758510
[TBL] [Abstract][Full Text] [Related]
6. Burden of illness in idiopathic pulmonary fibrosis.
Collard HR; Ward AJ; Lanes S; Cortney Hayflinger D; Rosenberg DM; Hunsche E
J Med Econ; 2012; 15(5):829-35. PubMed ID: 22455577
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation.
Loveman E; Copley VR; Colquitt J; Scott DA; Clegg A; Jones J; O'Reilly KM; Singh S; Bausewein C; Wells A
Health Technol Assess; 2015 Mar; 19(20):i-xxiv, 1-336. PubMed ID: 25760991
[TBL] [Abstract][Full Text] [Related]
8. Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.
Yu YF; Wu N; Chuang CC; Wang R; Pan X; Benjamin NN; Devercelli G; Coultas DB
J Manag Care Spec Pharm; 2016 Apr; 22(4):414-23. PubMed ID: 27023695
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Burden of illness in progressive fibrosing interstitial lung disease.
Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; Brown KK
J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
[No Abstract] [Full Text] [Related]
11. The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study.
Cox IA; de Graaff B; Ahmed H; Campbell J; Otahal P; Corte TJ; Moodley Y; Goh N; Hopkins P; Macansh S; Walters EH; Palmer AJ
Eur J Health Econ; 2023 Sep; 24(7):1121-1139. PubMed ID: 36289130
[TBL] [Abstract][Full Text] [Related]
12. Health care burden and medical resource utilisation of idiopathic pulmonary fibrosis in Korea.
Kim SW; Myong JP; Yoon HK; Koo JW; Kwon SS; Kim YH
Int J Tuberc Lung Dis; 2017 Feb; 21(2):230-235. PubMed ID: 28234090
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis.
Cichewicz A; Tencer T; Gupte-Singh K; Egodage S; Burnett H; Kumar J
Adv Ther; 2023 May; 40(5):2116-2146. PubMed ID: 37000363
[TBL] [Abstract][Full Text] [Related]
14. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.
Xie F; Kovic B; Jin X; He X; Wang M; Silvestre C
Pharmacoeconomics; 2016 Nov; 34(11):1087-1100. PubMed ID: 27339668
[TBL] [Abstract][Full Text] [Related]
15. Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study).
Rodríguez-Nieto MJ; Cano-Jiménez E; Romero Ortiz AD; Villar A; Morros M; Ramon A; Armengol S
Pharmacoeconomics; 2023 Aug; 41(8):999-1010. PubMed ID: 37249823
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study.
Raimundo K; Chang E; Broder MS; Alexander K; Zazzali J; Swigris JJ
BMC Pulm Med; 2016 Jan; 16():2. PubMed ID: 26732054
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis.
Kreuter M; Picker N; Schwarzkopf L; Baumann S; Cerani A; Postema R; Maywald U; Dittmar A; Langley J; Patel H
Respir Res; 2022 Mar; 23(1):62. PubMed ID: 35305632
[TBL] [Abstract][Full Text] [Related]
18. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic Pulmonary Fibrosis: Utilization of Health Services and Out-Of-Pocket Health Expenditures in Greece.
Naoum P; Athanasakis K; Skroumpelos A; Kyriopoulos J
Value Health Reg Issues; 2020 Sep; 22():44-48. PubMed ID: 32777730
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States.
Wu N; Yu YF; Chuang CC; Wang R; Benjamin NN; Coultas DB
J Med Econ; 2015 Apr; 18(4):249-57. PubMed ID: 25428658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
